Update shared on02 Sep 2025
Fair value Decreased 6.93%Despite a modest improvement in consensus revenue growth forecasts, Elekta’s future P/E multiple has edged lower, contributing to a reduced consensus analyst price target from SEK57.79 to SEK55.31.
What's in the News
- Elekta reiterated full-year sales growth guidance for 2025–2026 but expects continued near-term sales weakness in the US and lingering negative effects from prior low orders in China; FX and tariffs expected to pressure Q2 earnings, with hopes of Chinese sales recovery later in the year.
- Elekta's Leksell Gamma Knife system received FDA 510(k) clearance for treating refractory mesial temporal lobe epilepsy in adults, expanding its indications for non-invasive radiosurgery.
- Elekta partnered with Gray Oncology Solutions to integrate GrayOS, an AI-powered patient scheduling platform, with Elekta ONE OIS, enhancing operational efficiency for North American cancer care providers.
- Jakob Just-Bomholt was appointed Chief Executive Officer, effective September 1, 2025, bringing extensive international leadership experience to the company.
- Elekta acquired assets from its Croatian distributor and will establish an office in Zagreb to strengthen its regional market position and cancer treatment services.
Valuation Changes
Summary of Valuation Changes for Elekta
- The Consensus Analyst Price Target has fallen slightly from SEK57.79 to SEK55.31.
- The Consensus Revenue Growth forecasts for Elekta has risen from 4.3% per annum to 4.5% per annum.
- The Future P/E for Elekta has fallen slightly from 13.70x to 13.41x.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.